(Q39934229)

15 September 2017

Efficacy of IL-2- versus IL-15-stimulated CD8 T cells in adoptive immunotherapy (English)

1 reference

15 September 2017

1 reference

Katja Mueller

1

1 reference

15 September 2017

Oliver Schweier

series ordinal

2

1 reference

15 September 2017

Hanspeter Pircher

series ordinal

3

1 reference

15 September 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

European Journal of Immunology

15 September 2017

1 reference

15 September 2017

38

1 reference

15 September 2017

10

1 reference

15 September 2017

2874-2885

1 reference

Effector differentiation is not prerequisite for generation of memory cytotoxic T lymphocytes

15 September 2017

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

Initial antigen encounter programs CD8+ T cells competent to develop into memory cells that are activated in an antigen-free, IL-7- and IL-15-rich environment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

Rescue of CD8 T cell-mediated antimicrobial immunity with a nonspecific inflammatory stimulus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

Cancer immunotherapy: a treatment for the masses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Principles of adoptive T cell cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

CD8+ T-cell memory in tumor immunology and immunotherapy

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Improving T cell therapy for cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Differential regulation of T-cell growth by IL-2 and IL-15

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Clinical effects and toxicity of interleukin-2 in patients with cancer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Migratory properties of naive, effector, and memory CD8(+) T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Heterogeneity and cell-fate decisions in effector and memory CD8+ T cell differentiation during viral infection

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Control of homeostasis of CD8+ memory T cells by opposing cytokines.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

IL-15 and IL-2: a matter of life and death for T cells in vivo

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Interleukin-2 induction of T-cell G1 progression and c-myb expression

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

IL-15Ralpha recycles and presents IL-15 In trans to neighboring cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

IL-15, a novel T cell growth factor that shares activities and receptor components with IL-2.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Coordinate expression and trans presentation of interleukin (IL)-15Ralpha and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

The IL-15/IL-15Ralpha on cell surfaces enables sustained IL-15 activity and contributes to the long survival of CD8 memory T cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Transregulation of memory CD8 T-cell proliferation by IL-15Rα+ bone marrow–derived cells

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Dendritic cells prime natural killer cells by trans-presenting interleukin 15

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Immunotherapy through TCR gene transfer

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Cancer regression in patients after transfer of genetically engineered lymphocytes

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Quantification of lymphocytic choriomeningitis virus with an immunological focus assay in 24- or 96-well plates

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Fas involvement in Ca(2+)-independent T cell-mediated cytotoxicity

1 reference

https://api.crossref.org/works/10.1002%2FEJI.200838426

7 January 2021

Identifiers

DOI

10.1002/EJI.200838426

1 reference

15 September 2017

1 reference